Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tovorafenib in Japanese Paediatric Participants With BRAF-altered Recurrent or Progressive Low-grade Glioma
NCT07441707Phase 1Active, not recruiting
- Sponsor
- Ipsen
- Start
- Mar 2026
- Primary completion
- Jul 2030
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tovorafenib in glioma, sponsored by Ipsen. Primary endpoints: Percentage of participants experiencing Adverse Events and Adverse Events of Special Interest, Percentage of participants experiencing Serious Adverse Events and Adverse Events of Special Interest at 4 years and 10 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
tovorafenib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07441707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07441707.